# A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Source: https://onco.cc/trials/nct07103018/  
OnCo record `nct07103018` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of KTX-2001 run by K36 Therapeutics, Inc., now recruiting.

## Summary

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) is a phase 1 interventional study registered as NCT07103018 by K36 Therapeutics, Inc., with 144 participants planned, started 2025-11-21. Conditions recorded: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC and mCRPC (Metastatic Castration-resistant Prostate Cancer). Interventions recorded: KTX-2001 and KTX-2001 + Darolutamide (NUBEQA®).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07103018
- Phase: 1
- Setting: Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer
- Sponsor: K36 Therapeutics, Inc.
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT07103018: https://clinicaltrials.gov/study/NCT07103018

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [KTX-2001](https://onco.cc/drugs/ktx-2001/)
- companies: [K36 Therapeutics](https://onco.cc/companies/k36-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07103018.json